March 2006 Archive

Mar 24, 2006

A federal advisory panel came to the conclusion that drugs used to treat attention deficit hyperactivity disorder (ADHD) do not need to carry a “black-box” warning, the government’s strongest, alerting users of psychiatric and cardiovascular risks.

Mar 22, 2006

Following last month’s recommendation to add a “black box” warning about cardiovascular risks, attention deficit hyperactivity disorder (ADHD) drugs may also have to provide information about the possible risk of psychosis or mania.

Mar 15, 2006

A warning was issued to companies selling two dietary supplements with synthetic steroids—the products are illegal and can not be sold. According to the Food and Drug Administration (FDA), Anabolic Xtreme Superdrol and Methyl-1-P are sold as muscle builders but may cause serious long-term health problems.

Mar 13, 2006

Taking Plavix in addition to aspirin to prevent a first heart attack? You could be wasting your time. A study, soon to be published in The New England Journal of Medicine, found Plavix offered no benefit over low-dose aspirin treatment, and caused dangerous internal bleeding.

Mar 10, 2006

Controversial multiple sclerosis (MS) drug Tysabri is returning to the market after an unanimous vote by a Food and Drug Administration (FDA) advisory panel. The drug was recalled last year for causing the deadly brain disease progressive multifocal leukoencephalopathy (PML).

Mar 08, 2006

Dozens of multiple sclerosis (MS) patients urged the Food and Drug Administration (FDA) to return Tysabri to the market. The patients stated, in heartfelt testimonies, that the drug eased the strains of the disease.

Mar 07, 2006

Another Vioxx trial is underway, but this is the first case involving long-term use of the drug. Two New Jersey men, Thomas Cona and John McDarby, are suing Merck for heart attacks they suffered after taking Vioxx for extended periods of time.

Mar 06, 2006

Drug makers aren’t keeping their promises, according to the Food and Drug Administration (FDA). Drug trials slated to detect the effectiveness of drugs and if they produce any unwanted side effects are never taking place. Now, the FDA is being criticized for not being tough enough on drug manufacturers that make these promises in order to get their drugs on the market more quickly.

Mar 01, 2006

The Food and Drug Administration (FDA) is under pressure to ban a pain reliever blamed for more than 2,000 deaths. Darvocet, also known as Darvon, provides poor pain relief at a significant risk, claims the Public Citizen consumer group. They are calling for the FDA to pull it from the market.